Clinical Trial Update: Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the efficacy, safety, and tolerability of vixarelimab in reducing pruritus for patients with prurigo nodularis has completed and posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prurigo Nodularis

Drugs mentioned

• Vixarelimab (vixarelimab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Prurigo Nodularis, Pruritis | Phase 2 | Status: COMPLETED | Results posted: 2026-01-13